Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 76Neoplasm Metastasis 13Stomach Neoplasms 12Neoplasms 8Breast Neoplasms, Male 8Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 6Endometrial Neoplasms 6Esophageal Neoplasms 5Colorectal Neoplasms 5Brain Neoplasms 5Ovarian Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Squamous Cell Carcinoma of Head and Neck 3Inflammatory Breast Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Vulvar Neoplasms 2Vipoma 2Vaginal Neoplasms 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Testicular Neoplasms 2Somatostatinoma 2Solid Tumor 2

Interventions

pembrolizumab 2tislelizumab 1Trastuzumab 1Imatinib Mesylate 1GSK-3326595 1Cyclophosphamide 1Blood Specimen Collection 1BMS-906024 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Adenoid Cystic × Trastuzumab × Clear all
NCT03680560 2020-03-31

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

Cogent Biosciences, Inc.

Phase 1 Terminated
6 enrolled
BreastGastrointestinal

Breast Neoplasms, Carcinoma, Adenoid Cystic, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡